"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 31 | 31 |
| 2004 | 0 | 61 | 61 |
| 2005 | 1 | 62 | 63 |
| 2006 | 0 | 63 | 63 |
| 2007 | 0 | 91 | 91 |
| 2008 | 0 | 77 | 77 |
| 2009 | 1 | 93 | 94 |
| 2010 | 1 | 105 | 106 |
| 2011 | 0 | 89 | 89 |
| 2012 | 1 | 114 | 115 |
| 2013 | 0 | 112 | 112 |
| 2014 | 1 | 133 | 134 |
| 2015 | 0 | 126 | 126 |
| 2016 | 0 | 121 | 121 |
| 2017 | 0 | 102 | 102 |
| 2018 | 0 | 98 | 98 |
| 2019 | 1 | 96 | 97 |
| 2020 | 0 | 81 | 81 |
| 2021 | 0 | 79 | 79 |
| 2022 | 0 | 26 | 26 |
| 2023 | 0 | 31 | 31 |
| 2024 | 0 | 70 | 70 |
| 2025 | 0 | 46 | 46 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. Clin Transl Sci. 2026 Mar; 19(3):e70508.
-
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nat Commun. 2025 Dec 10; 16(1):11246.
-
Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness. Genes Dev. 2025 Oct 01; 39(19-20):1219-1240.
-
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025 Oct; 646(8086):953-962.
-
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res. 2025 Sep 15; 85(18):3471-3489.
-
A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells. J Vis Exp. 2025 Aug 22; (222).
-
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood. 2025 Aug 21; 146(8):971-983.
-
DGAT1 Inhibition Enhances Olaparib-Induced Lipotoxic Apoptosis in Metastatic Castration-Resistant Prostate Cancer. FASEB J. 2025 Aug 15; 39(15):e70925.
-
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia. Sci Adv. 2025 Aug 15; 11(33):eadv7648.
-
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.